IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds who had shorted the stock.
And bleeds seen with the “transformative” project were played down.
Waning factor VIII levels with giroctocogene fitelparvovec once again raise the spectre of Biomarin’s valrox.
And both companies’ pyruvate kinase R activators could have Global Blood looking over its shoulder, though pain crises sow doubts.
Sellside firefighting has saved the day for IGM, but Ash hears of some pretty potent anti-CD20 competition for the company.
Results with Loxo-305 could justify Lilly’s acquisition of Loxo, but its inventor, the UK’s Redx, can just read ‘em and weep.
With funding in place, Syros is pushing its lead leukaemia project into pivotal development, and has a newly acquired second asset not far behind.
While projects against BCMA abound, two little-known multiple myeloma targets make bids for attention at Ash.
The latest showing from Car-T players in multiple myeloma sees Johnson & Johnson beat Bluebird, but toxicity hangs over both.
Data in three more patients support Crispr and Vertex’s hope of developing a functional cure for beta-thalassaemia and sickle cell disease.
The group had already fallen on its Ash abstract release, and today’s presentation offers little fresh hope.